Significant changes may be on the horizon resulting from a pending decision by the DEA to reschedule cannabis to a Schedule 3 substance. The DEA has never rejected a recommendation from the U.S. Department of Health and Human Services, so assuming this recommended rescheduling occurs, this will have a massive impact on the cannabis industry. Join us for a comprehensive exploration of the potential impact on accounting, taxation, mergers and acquisitions, startup ventures, and exits within the cannabis sector.
Learning Objectives:
DOPE CFO
Founder and Owner
[email protected]
(405) 990-4370
Andrew founded DOPE CFO and is an expert in cannabis startups, CFO services, turnaround and high-growth strategies, capital sourcing, mergers, exits, and wealth protection. He has served in the "Big 4," including PriceWaterhouseCoopers, and is the winner of the 1995 Gold Medal Award for the CPA exam’s highest score. Andrew was runner up for Portland Business Journal's CFO of the Year in 2017, making him the first cannabis CFO ever to be nominated.